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Introduction
Intra-aortic balloon counterpulsation pump (IABP) therapy
has been used in several clinical situations, predominantly
in critically ill patients, since 1968 [1]. In acute myocardial
infarction (AMI) patients who are experiencing continued
ischemia, IABP therapy may be used in an attempt to
improve patency of an infarct-related coronary artery (IRA)
and reduce the rates of recurrent myocardial ischemia and
its sequelae. The mechanism for this benefit is thought to
be a combination of reduced oxygen demand [2],
increased coronary artery blood flow velocity [3], and aug-
mentation of diastolic arterial pressure enhancing throm-
bolysis, leading to faster reperfusion [4]. IABP therapy may
also be used in patients with ventricular septal rupture,
severe mitral regurgitation, and cardiogenic shock.
The technique for IABP therapy involves insertion of an 8 or
9.5 Fr helium-filled balloon via the femoral artery into the
descending aorta. The device is preferably inserted
through an existing vascular access site in an attempt to
reduce the rate of vascular and hemorrhagic complications.
It is crucial that the tip be positioned distal to the left sub-
clavian artery, but proximal to the renal arteries. The balloon
is synchronized to deflate during early systole, thus
decreasing left ventricular (LV) afterload. In turn, LV ejec-
tion fraction (EF) and stroke volume (SV) are enhanced,
leading to reduced myocardial oxygen consumption. The
balloon inflates during early diastole, thus increasing coro-
nary blood flow and peripheral perfusion. The IABP is usu-
ally commenced at a rate of 1 : 1. Once the benefit of IABP
therapy is thought to be concluded, patients are usually
gradually weaned from the pump at rates of 1 : 2 to 1 : 3
over 6-12 h.
Following the procedure, one must ensure that the patient
has adequate radial artery pulses, suggesting no IABP
interference with the subclavian arteries. A chest roentgen-
ogram should be inspected for the location of the IABP
marker, which should be 1-2 cm below the aortic arch
knuckle. The patient's serum creatinine and urine output
should be followed for evidence of IABP interference with
the renal arteries. When used to prevent recurrent ischemia
post-AMI, all patients who receive IABP therapy should
also be prescribed daily aspirin and systemic heparinization
with 1000-2000 U/h infused for at least 48 h to maintain
activated partial thromboplastin time (aPTT) between 50
and 84 s.
Contraindications to IABP use include severe peripheral
vascular disease (PVD), defined as diminished femoral
pulses or absent pedal pulses; aortic valve regurgitation
(AVR); aortic dissection; tortuous or aneurysmal descend-
ing thoracic or abdominal aorta; and patients unable to be
systemically heparinized. IABP therapy does not prohibit
the use of other medications often used in AMI patients,
including aspirin, systemic heparinization, angiotensin-con-
verting enzyme inhibitors, intravenous nitroglycerine, and
beta blockers.
Complications of IABP therapy may include limb ischemia
and hemorrhage to the femoral access site. A recently
developed technique of sheathless insertion may reduce
the rate of limb ischemia [5].
Review methods
We performed a computerized search of MEDLINE to iden-
tify any randomized trials or economic analyses of IABP
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treatment. Terms used were `prospective studies, rand-
omized controlled trial, clinical trial, economic analysis,
intra-aortic balloon counterpulsation pump'. We also
scanned reference lists for English language studies evalu-
ating IABP treatment vs control treatment using randomiza-
tion methods.
Results from randomized clinical trials of IABP 
therapy in AMI patients
As with all analyses of interventions used to treat AMI
patients, IABP therapy must be subdivided into the pre-and
post-thrombolytic eras. Two small randomized trials in the
prethrombolytic era, enrolling a total of 50 patients, failed to
show a survival benefit, reduction in infarct size, or improve-
m e n t  i n  g l o b a l  L V  f u n c t i o n  [6,7]. Although thrombolytic
therapy has greatly improved the prognosis of patients with
AMI, the inhospital mortality rate of AMI patients with car-
diogenic shock remains as high as 55% [8]. The main
cause for early mortality (within 48 h of onset of AMI symp-
toms) in thrombolytic-treated patients is LV failure [9]. In the
post-thrombolytic era there have been three randomized tri-
als of prophylactic IABP therapy in AMI patients.
In 1994, the Randomized IABP Trial, which enrolled 182
patients from 11 centers, evaluated the benefit-risk ratio of
IABP during the early phase of AMI [10]. Inclusion criteria
were an emergency cardiac cathererization within 24 h of
an AMI which demonstrated an occluded IRA at first angi-
ography, and restored IRA patency by primary angioplasty
(n = 106), intracoronary thrombolysis (n = 25), or rescue
angioplasty following failed thrombolysis (n = 51). Exclu-
sion criteria were hemodynamic instability necessitating the
use of an IABP (it was considered unethical to withhold
IABP therapy from such patients), severe PVD, bleeding
diathesis prohibiting the use of extended intravenous
heparin therapy, or IRA patency at first angiography. This
study randomized patients at the end of cardiac catheteri-
zation or angioplasty to receive 48 h of prophylactic IABP
therapy (n = 96) or standard care (n = 86). The primary
endpoints was IRA reocclusion at 5- to 7-day repeat quan-
titative coronary angiography (QCA), which was performed
in 162 (89%) of the patients. Only 8% of patients rand-
omized to IABP had IRA reocclusion during this short-term
follow-up, compared to 21% of controls (P < 0.03). The
secondary endpoint was a composite inhospital clinical
endpoint of death, stroke, reinfarction, emergency revascu-
larization, or recurrent ischemia. This composite secondary
endpoint occurred in 13% of IABP patients, compared with
24% of controls (P < 0.05). No significant differences were
observed between the two groups with regards to severe
bleeding complications, vascular repair, or thrombectomy.
In 1996, Kono et al[11] published the results of a trial which
enrolled 45 patients with AMI from one center in Japan.
Patients were included if their AMI was unsuccessfully
treated with thrombolysis (tPA within 12 h of onset of symp-
toms). Failed thrombolysis was identified by coronary angi-
ography, performed 1 h after initiation of intravenous
thrombolysis, which revealed persistent occlusion or partial
reperfusion of the IRA. Rescue angioplasty was not
attempted in any of these patients. This study randomized
patients at the end of initial coronary angiography to 48 h
of prophylactic IABP therapy (n = 23) or standard care (n
= 22). The primary endpoint was IRA patency (defined as
Thrombolysis in Myocardial Infarction flow grade 3) 3
weeks after AMI. Significantly more patients in the IABP
therapy group had IRA patency than patients randomized to
standard care (74% vs 32%, P < 0.05). The secondary
endpoints were recurrent ischemia, malignant ventricular
dysrhythmias, death, stroke, or need for coronary artery
bypass grafting. There were no statistically significant dif-
ferences in any of these clinical endpoints between the
IABP and standard therapy groups at 3-week follow-up. As
with the Randomized IABP Trial, there were no significant
differences observed between the two groups with regard
to severe bleeding complications, vascular repair, or
thrombectomy.
In 1997, the Second Primary Angioplasty in Myocardial Inf-
arction (PAMI-II) trial determined the role of prophylactic
IABP therapy after primary angioplasty in AMI patients [12].
This trial enrolled 437 high-risk, but hemodynamically sta-
ble patients from 34 centers worldwide. Inclusion criteria
were ongoing chest pain up to 12 h in duration, electrocar-
diographic (ECG) evidence of AMI, an occluded coronary
artery with regional LV dysfunction, and high-risk status
(one or more of age > 70 years, three-vessel coronary
artery disease, LV EF < 46%, saphenous vein graft occlu-
sion, persistent malignant ventricular dysrhythmias, or a
suboptimal angioplasty result). Exclusion criteria were
hemodynamic instability necessitating the use of an IABP,
cardiogenic shock, bleeding diathesis prohibiting the use
of aspirin or heparin, precatheterization administration of
thrombolytic therapy, PVD, aortic aneurysm, and AVR. This
study randomized patients at the end of primary angioplasty
to receive 36-48 h of prophylactic IABP therapy (n = 211)
or standard care (n = 226). The primary endpoint was a
composite predischarge clinical endpoint of death, stroke,
reinfarction, IRA reocclusion, new onset congestive heart
failure (CHF), or sustained hypotension. There was no sta-
tistically significant difference in this composite endpoint
between IABP (28.9%) and standard therapy (29.2%)
groups (P = 0.95). However, significantly more IABP ther-
apy patients had an inhospital stroke than those treated
with standard therapy (2.4% vs 0, P = 0.03). PAMI-II con-
cluded that major benefits or hazards of routine prophylac-
tic IABP therapy are unlikely to exist.
The reason why the Randomized IABP Trial demonstrated
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be the fact that the control group in PAMI-II had a better
than expected outcome. Most notably, the IRA reocclusion
rate in the standard therapy group in PAMI-II was 5.5%,
compared to 20.8% in the Randomized IABP Trial control
group. This was an unexpected finding, since patients in
PAMI-II were generally older and had poorer LV function
than those in the Randomized IABP Trial.
Critical appraisal of randomized clinical trials 
of IABP therapy in AMI patients
Thorough critical appraisal involves determining the validity
of the study design, understanding the results and deciding
whether and how the results may be applied in practice.
The factors to consider when critically appraising articles
on therapy are summarized in Table 1[13–15].
In determining the validity of a therapeutic article, we ask
whether the results represent an unbiased estimate of the
treatment effect [13]. First, we ask if the assignment of
patients was randomized? In the Randomized IABP Trial
[10], randomization took place at the end of the initial emer-
gency catheterization, before the patient was transferred to
the critical care unit (CCU). The randomization was strati-
fied by clinical site, and utilized permuted block randomiza-
tion within each center to maintain chronological balance in
the number of patients allocated to each treatment arm. In
the trial by Kono et al[11], patients were enrolled using a
predetermined randomization list along with sealed enve-
lopes. The PAMI-II trial [12] did not state their exact method
of randomization. Although there is no direct evidence in
either of these three trials of lack of concealment, a situa-
tion where a clinician may know in advance that a patient
will be allocated to either the treatment or placebo group,
this possibility cannot be excluded.
The second question to address when determining validity
is whether all patients who entered the study were
accounted for and attributed at its conclusion. In the Rand-
omized IABP Trial [10], only 162 (89%) of the 182 rand-
omized patients had 5- to 7-day follow-up QCA. The
reasons for lack of angiographic follow-up were death
(two), coronary artery bypass graft (CABG) surgery before
follow-up QCA (five), patient refusal (seven), and medical
contraindication (six). Follow-up for the composite clinical
endpoint, however, was 100%. In the trial by Kono et
al[11], 3-week follow-up for QCA and clinical endpoints
was 100%. In PAMI-II [12], only 330 (85%) of 389 eligible
patients had predischarge follow-up QCA, although the
composite predischarge clinical endpoint was determined
on all patients. It is crucial that clinical endpoint follow-up is
complete, otherwise bias may be introduced, since patients
who are lost often have different prognoses from those who
are retained. Neither the Randomized IABP Trial nor PAMI-
II performed a sensitivity analysis on the QCS follow-up
data.
Another important aspect of follow-up relates to whether
patients were analyzed in the groups to which they were
randomized. In the Randomized IABP Trial [10], although
seven (8%) standard therapy patients crossed-over to the
IABP group, and nine (9%) IABP therapy patients required
premature termination of the IABP within 24 h, analysis was
conducted on an intention-to-treat basis. Similarly, in PAMI-
II [12], although 26 (12%) standard therapy patients
received an IABP, and 29 (14%) patients randomized to
IABP did not receive the device, analysis was also con-
ducted on an intention to treat basis.
An important secondary guideline in determining validity
relates to whether patients, clinicians, and study personnel
were blinded, thus preventing observer bias and cointer-
vention. In the Randomized IABP Trial [10], it was not
stated if the physicians analyzing the QCA films were
blinded. Kono et al[11] stated the QCA results were ana-
lysed in a blinded manner, but did not provide specifics of
this blinding process. In PAMI-II [12], the independent core
laboratory angiographic analysis was performed by a tech-
nician in a single-blinded manner with regard to the rand-
omization scheme.
We also need to determine if the study groups were similar
at the start of the trial, since randomization does not always
produce groups balanced for known prognostic factors. In
the Randomized IABP Trial [10], the baseline clinical and
angiographic characteristics in the two groups were simi-
lar, except that the IRA was more frequently the left anterior
descending coronary artery in IABP therapy patients (49%
vs 35%; P value not stated). Conversely, more standard
therapy patients had the right coronary artery as the IRA
(54% vs 34%; P value not stated). In both the trial by Kono
et al[11] and PAMI-II [12], patient groups were well
matched following randomization.
Another assessment of validity related to whether the
groups were treated equally, aside from the experimental
intervention. In the Randomized IABP Trial [10], angioplasty
was used to restore patency in 90% of patients later rand-
omized to IABP therapy, and 83% later assigned to stand-
ard care. Intracoronary thrombolysis was used in 42% of
patients later randomized to IABP therapy compared to
46% of patients in the standard therapy arm. Intravenous
heparin was used for a mean of 5 days in both the IABP and
standard therapy arms. In Kono et al's trial [11] and PAMI-
II [12], thrombolysis and primary angioplasty, respectively,
were used exclusively. In none of these three trials was
there evidence of contamination, a situation where control
patients accidentally receive experimental treatment, or
cointervention, a circumstance where additional diagnostic
or therapeutic procedures are performed on experimental,
but not control, patients.Critical Care   Vol 2 No 1    Peterson et al.
Once the validity of a clinical trial is established, we can
then focus on the results. The first consideration is the size
of the treatment effect. Results from the Randomized IABP
trial [10] suggest that eight patients needed to be treated
with prophylactic IABP therapy for 48 h to prevent one
patient from developing IRA reocclusion 5- to 7-days post-
AMI. Furthermore, 13 patients needed to be treated with an
IABP to prevent one patient from sustaining an inhospital
death, stroke, reinfarction, emergency revascularization, or
recurrent ischemia. Kono et al's trial [11] suggested better
results, where only two patients needed to receive IABP
therapy for 48 h to enable the IRA to be patent in one
patient 3 weeks post-AMI. PAMI-II [12] demonstrated
equivalence between IABP and standard therapy, although
for every 42 patients treated with an IABP, one extra stroke
resulted (P = 0.03). Not only is the size of the treatment
effect important, but so too is the precision. Unfortunately,
neither of these three trials reported 95% confidence
intervals.
In determining the clinical application of an article on ther-
apy, we ascertain if the results are useful in practice. The
results of the Randomized IABP Trial [10] are applicable to
patients with AMI undergoing immediate cardiac catheteri-
zation. However, the Randomized IABP Trial confirmed pre-
vious observational data [16,17] that IABP therapy is
particularly important in situations in which IRA patency is
critical for survival, such as in patients with cardiogenic
shock. In addition, both the Randomized IABP [10] and
PAMI-II [12] trails did enrol patients in numerous centers
ranging from community hospitals to large academic cent-
ers, suggesting their respective results may be generaliza-
ble to most hospitals commonly using IABP. Only high-risk
patients were included in PAMI-II, and no patients in Kono
et al's trial received rescue angioplasty. The therapeutic
maneuver in these trials, specifically insertion and use of an
IABP, is described in sufficient detail and is available,
acceptable and affordable in many centers caring for criti-
cally ill patients.
These three trials generally met other important considera-
tions when determining the clinical application of a thera-
peutic article; namely, both statistical and clinical
significance were considered, and all clinically important
outcomes (both beneficial and adverse), other than quality
of life issues, were assessed objectively and reported.
Whether the resources required to use IABP are better
spent pursuing this, rather than some other intervention, will
be discussed below when considering the economics of
IABP therapy.
Economic analysis of IABP therapy in AMI 
patients
The economic implications of prophylactic IABP in sustain-
ing IRA patency are worth considering. A reduction in
recurrent ischemia and repeat revascularization procedures
may initially lead to reduced costs, but the expense of
inserting an IABP and potential peripheral vascular and
hemorrhagic complications arising from its use may offset
these initial cost savings.
An economic analysis of the Randomized IABP Trial was
recently performed on 102 patients (from three centers)
(56%) of the 182 patients from the original 11 participating
centers [18]. Hospital bills for this subset of patients rand-
omized to either 48 h of IABP or standard therapy were
assessed using each hospital's Medicare cost report billing
data and correction factors to convert charges to costs.
Thus, the specific subtype of economic appraisal per-
formed was a form of cost-benefit analysis, since it meas-
ured both resources used and health effects in monetary
units. The results are expressed in dollar values, rather than
as costs per quality adjusted life year (QALY). However,
unlike traditional cost-benefit analyses, this paper did not
value health consequences by asking patients what they
would be willing to pay for health services that achieve out-
comes of particular types. By expressing both costs and
health benefits in monetary units, Talley et al[18] facilitate
the calculation of IABP therapy's net benefit, which gives
policy decision-makers a single measure of its desirability
from an efficiency perspective.
Critical appraisal of the economic analysis of 
IABP therapy in AMI patients
The factors which we consider when critically appraising an
economic analysis are summarized in Table 2[19,20]. In
determining the validity of an economic analysis, we ascer-
tain if the results yield an unbiased assessment of the costs
Table 1
Factors to be considered when critically appraising articles on 
therapy
Validity
Primary guides
Was assignment of patients to treatments really randomized?
Were all patients who entered the study accounted for and
attributed at its conclusion?
Secondary guides
Were patients, clinicians, study personnel blinded?
Were the groups similar at the start of the trial?
Aside from experimental intervention, were the groups treated
equally?
What were the results?
How large was the treatment effect?
How precise was the treatment effect?
Clinical application
Are the results applicable to my patients?
What is the net impact of the treatment?Available online http://ccforum.com/content/2/1/3
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and outcomes, and whether the economic analysis truly
determines which of the clinical strategies provides the
most benefit for the available resources. The first consider-
ation in assessing validity is whether the analysis provides
a full economic comparison of healthcare strategies. Talley
et al.'s cost-benefit analysis [18] compared all relevant clin-
ical strategies by determining total index hospitalization
costs from admission to discharge, including all diagnostic
and therapeutic procedures, as well as all outcomes,
including angiographic and clinical complications. The
viewpoint adopted by this analysis, however, was not broad
since data for this economic analysis was only based on
inhospital billings. It may be argued that from an economic
standpoint, the advantages or disadvantages of IABP ther-
apy may be eroded if the costs incurred during a longer
duration of postdischarge follow-up were analyzed. Fur-
thermore, quality of life issues were not estimated.
The next question to address is whether all relevant costs
and outcomes were properly measured and valued. It is
questionable whether this analysis established the true clin-
ical effectiveness, since the design of the Randomized
IABP Trial involved mandatory 5- to 7-day repeat QCA.
Some patients with occluded coronary arteries remain clin-
ically silent, and because repeat QCA does not always
occur in clinical practice as it did in this trial, Talley et al[18]
should have adjusted their analysis to assume that incom-
plete efficacy is actually achieved in clinical practice. Talley
et al's costs were measured accurately by applying correc-
tion factors to convert charges and costs.
There are two secondary guides to consider when deter-
mining the validity of an economic analysis. Talley et al[18]
did not perform a sensitivity analysis, and thus appropriate
allowances were not made for uncertainties in the analysis.
Costs and outcomes were, however, related to different
baseline risks within the treatment population, and these
results are discussed below.
After the validity of the economic analysis has been estab-
lished, determining the incremental costs and outcomes of
each strategy is the first component one assesses when
examining the results. The overall inhospital costs for
patients who received an IABP were not significantly
increased ($22,367 ± $14,369) compared to those who
did not ($19,211 ± $8414; P = 0.45). The authors there-
fore concluded that IABP provided a better clinical out-
come without substantially increasing hospital costs. Talley
et al[18] also determined whether the incremental costs
and outcomes differed between subgroups. Patients who
received an IABP and also developed recurrent ischemia
had significantly higher inhospital costs ($23,125 ±
$7690) compared to patients who had recurrent ischemia
but were not randomized to IABP therapy ($20,416 ±
$12,449; P = 0.02). Similarly, patients who experienced an
adverse composite clinical secondary endpoint and
received an IABP had significantly higher costs ($25,598
± $10,024) than similar patients not randomized to IABP
therapy ($19,790 ± $12,045; P = 0.002). However, a sen-
sitivity analysis was not used to assess the robustness of
the conclusions.
In determining the clinical application of an economic anal-
ysis, clinicians determine whether the results are useful in
practice. Given that IABP therapy produces higher inhospi-
tal costs, but a better clinical outcome (at least in the Ran-
domized IABP Trial), we ask if the added treatment effect is
worth the added costs? Talley et al[18] did not calculate
incremental cost-effectiveness ratios of IABP therapy, thus
leaving the issue of the trade-off between increased costs
and possibly increased effectiveness unresolved. Given
that the Randomized IABP Trial was undertaken in a variety
of community hospitals and academic centers, it is reason-
able to assume that similar health outcomes and costs
could be expected from using IABP therapy, provided one's
center has competent clinicians to insert the devices.
Conclusion
The potential benefits of careful use of IABP therapy are
unlikely to be offset by vascular and hemorrhagic
complications. In the final analysis of IABP cost-effective-
ness, clinicians and institutions need to decide what health
benefits will be foregone from other treatments or pro-
grams if resources are diverted instead to routine IABP
prophylaxis post-AMI.
Table 2
Factors to be considered when critically appraising an economic 
analysis
Validity
Primary guides
Did the analysis provide a full economic comparison of health care
strategies?
Were all relevant costs and outcomes properly measured and 
valued?
Secondary guides
Was appropriate allowance made for uncertainties in the analysis?
Are estimates of costs and outcomes related to the baseline risk in
the treatment population?
What were the results?
What were the incremental costs and outcomes of each strategy?
Do incremental costs and outcomes differ between subgroups?
How much does allowance for uncertainty change the results?
Clinical application
Are the treatment benefits worth the costs and potential harms?
Could my patients expect similar health outcomes from using the
intervention?
Could I expect similar costs?Critical Care   Vol 2 No 1    Peterson et al.
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